Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Zasocitinib is also being evaluated in a head-to-head study against Bristol Myers Squibb’s Sotyktu (deucravacitinib) in ...

Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.

Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

Depo Provera’s label change comes amidst a flurry of over 2,000 lawsuits from women alleging that the contraceptive caused ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

INCOG BioPharma Services has announced an injectable drug manufacturing expansion at its Fishers facility in Indiana, US.

J&J has received the US FDA approval for Rybrevant Faspro, a SC administered therapy to treat patients with EGFR-mutated ...

The EC has approved Incyte’s Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory FL.

Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.